Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571

NCT02127372 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

43

Enrollment

OTHER

Sponsor class

Stopped The study was closed due to poor accrual

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Docetaxel, Cisplatin and STI571
DRUG: Docetaxel
DRUG: Cisplatin

Sponsor

Duke University